On Wednesday, USC football officially signed its top-ranked 2026 recruiting class. After largely sticking together for many months, at long last, the group is officially Trojans. USC pulled in a class ...

My Hero Academia’s final episode sparked overwhelming fan reactions as viewers celebrated Deku’s journey and the emotional ...

North Carolina is seeking $1 billion from the federal government for a wide-ranging plan that could reshape rural health care across the state. The N.C. Department of Health and Human Services hopes ...

Buffalo Gap defeated Riverheads 48-21 to win the Region 1B championship. Isaac Goff scored seven touchdowns and rushed for 244 yards for the Bison. The victory ended a 19-game losing streak for ...

Springboks coach Rassie Erasmus has responded to criticism of him giving a thumbs up to the crowd – which was mistaken for trolling his critics – after South Africa beat Ireland at the Aviva Stadium ...

Now that both the My Hero Academia manga and anime are finally over, it’s the perfect time to take a look back at this shōnen series’ iconic protagonist, Izuku Midoriya (AKA ...

Garland is sketching out one of North Texas’ biggest suburban makeovers, drafting a long-range blueprint to transform Lake Ray Hubbard shoreline into a string of mixed-use projects. The proposal to ...

Estevao won the battle of the wonderkids after scoring in Chelsea's 3-0 Champions League win over Barcelona on Tuesday (November 25). Chelsea took the lead at Stamford Bridge through a Jules Kounde ...

Families of roughly 300 United States citizens killed or injured in the Oct. 7, 2023, attack on Israel have filed a lawsuit alleging that Binance facilitated more than $1 billion in crypto transfers ...

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at ...

The MarketWatch News Department was not involved in the creation of this content. ZYNLONTA(R) in combination with glofitamab (COLUMVI(R)) demonstrated an 89.8% ORR and 77.6% CR across the 49 ...